Diabetes: Glucose Testing Strips Recalled
What weve been doing in the past, we looked at cholesterol and tried to find risks for heart disease, and we looked at blood sugar for risks for diabetes, HDL Chief Medical Officer Tara Dall said by phone. Those markers commonly dont pick up on those who are at greatest risk. There are so much better technologies to understand what somebodys future is for heart disease and diabetes. Not Immune Dall said its critical for professional athletes to realize that, even though theyre in top physical shape, theyre not immune to the risks of diabetes and heart disease due to genes and lifestyle. If we can understand that and intervene with a healthy lifestyle and addressing genetic risks, it will make a big difference, Dall added.
For the original version including any supplementary images or video, visit http://www.bloomberg.com/news/2013-08-13/redskins-team-with-hdl-on-advanced-heart-disease-diabetes-tests.html
A spokesman for the watchdog told Sky News that the readings could mislead patients to such an extent that they suffer hypoglycaemia – low blood sugar – which can result in a loss of consciousness. The strips were sold in British pharmacies between October and November 2012. Two batches of the GlucoMen LX Sensor test strips are affected The affected containers, which are stamped with lot numbers 3212219249 and 3212214249, expire on August 31, 2014 and are no longer on sale. Other batches are unaffected by the fault. There are no reports at present of patients being harmed by using the strips, which are manufactured in Italy byMenarini. Bridget Turner, director of policy and care improvement at Diabetes UK , said: “We would urge people with diabetes who use testing strips to follow advice from the MHRA and check their test strips to see if they are from these batches. “If they are, they should not use them and take them back to their pharmacist or their GP.” There are an estimated three million diabetics in the UK.
For the original version including any supplementary images or video, visit http://news.sky.com/story/1128593/diabetes-glucose-testing-strips-recalled
Conversant Bio Releases Comprehensive Diabetes Research Reference E-Book
“It’s a tight link,” said Gardell. “When fat accumulates,” he explained, “it can build up in fat tissue or in muscle tissue. Those individuals who tend to deposit more fat in their muscle tissue are more prone to diabetes.” When fat accumulates in muscles, it impairs their ability to absorb glucose from the bloodstream. That leads to insulin resistance, and ultimately to Type 2 diabetes. The collaboration is particularly promising “because we’re linking two companies that have synergistic skill sets,” said Gardell. While Sanford-Burnham officials would not say how much money Pfizer was investing in the project, they did say the collaboration was a great example of how the research center is working to diversify its revenue stream. Since the federal government has cut back on its research funding and grants, science institutes have had to rely more on private funding.
For the original version including any supplementary images or video, visit http://www.orlandosentinel.com/health/os-sanford-burnham-pfizer-collaborate-20130813,0,974004.story
Sanford-Burnham, Pfizer collaborate on diabetes discovery
Hunstville, Alabama (PRWEB) August 14, 2013 Conversant Bio, a global leader in supplying the highest quality human tissue and viable cell samples, today announced it is releasing a new E-book to help scientists researching diabetes better understand the nature of the disease, a diabetic patients lifestyle, the diagnosis process, common treatments and how to procure high-quality samples for drug discovery research efforts. The E-book, The Ultimate Diabetes in Research Reference Guide, is available for free download on the companys website at: http://www.conversantbio.com/ultimate-diabetes-in-research-reference-guide . Today, there are 26 million people with diabetes who live in the United States and there are approximately 86 million who are undiagnosed or have pre-diabetes. Because diabetes can be the catalyst of or complicate so many other health issues, there is a strong need to pool resources in order to help improve patient lifestyles for the long-term. For scientists refocusing their R&D efforts to make this happen, it is imperative that they understand how the disease functions in the real world outside of the lab. In this new E-book, Conversant Bio breaks down the basics on diabetes, highlights current statistics, differentiates between Type I and Type II, walks researchers through the process of diagnosing diabetes, and dives into various treatment methods. The guide also reveals how scientists can go about procuring quality human tissue biospecimens for their research.
For the original version including any supplementary images or video, visit http://www.sfgate.com/business/press-releases/article/Conversant-Bio-Releases-Comprehensive-Diabetes-4731813.php